activate GPR119 in the intestine and thereby stimulate the intestinal GLP-1 release. Said compounds can be used for the prophylaxis and/or treatment of diabetes-2, obesity, insulin resistance, and cardiovascular disease.Accordingly, in a first main aspect the invention relates to a compound ...
to determine one or more parameters indicative of the user's lung function. This is an important feature of the inhaler, since the user then only needs one single device for medication as well as to test the lung function, which is important in the correct medication of a lung disease. ...